Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q2 2026 · 10-Q
Revenue$161.28M$161.28M+34.6% vs Q2 2025 Net Income-$9.79M-$9.79MN/M vs Q2 2025 EPS Diluted-$0.08-$0.08N/M vs Q2 2025 Operating Income-$4,616,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$11,032,000N/M Margins · derivedOperating margin-2.9%+6.5 pt vs Q2 2025
Net margin-6.1%+8.1 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end